DaVita Inc. (DVA)

56.58
0.67 1.20
NYSE : Health Services
Prev Close 55.91
Open 56.46
Day Low/High 56.02 / 57.01
52 Wk Low/High 43.40 / 79.11
Volume 3.03M
Avg Volume 2.66M
Exchange NYSE
Shares Outstanding 160.30M
Market Cap 9.27B
EPS 0.90
P/E Ratio 17.16
Div & Yield N.A. (N.A)

Latest News

DaVita Announces New Senior Secured Credit Agreement

DaVita Announces New Senior Secured Credit Agreement

DENVER, Aug. 12, 2019 /PRNewswire/ -- DAVITA INC.

DaVita Inc. 2nd Quarter 2019 Results

DaVita Inc. 2nd Quarter 2019 Results

DENVER, Aug. 1, 2019 /PRNewswire/ -- DaVita Inc.

See How DaVita Ranks Among Analysts' Top Picks With Strong Buyback Activity

See How DaVita Ranks Among Analysts' Top Picks With Strong Buyback Activity

A study of analyst recommendations at the major brokerages shows that DaVita Inc is the #65 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period.

Innovation In Home Care Delivery Improves The Quality Of Life For More Kidney Patients

Innovation In Home Care Delivery Improves The Quality Of Life For More Kidney Patients

Company reports steady growth of home-based treatments

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DVA, HTZ, JAZZ, SKIS, SYKE Downgrades: SLAB, TZOO, VFC Initiations: OBNK, STXB Read on to get TheStreet Quant Ratings' detailed report:

DaVita Soars on Upbeat Earnings Guidance

DaVita Soars on Upbeat Earnings Guidance

The kidney dialysis services provider expects its second-quarter profit to be higher than expected.

DaVita Commences Self-Tender Offer To Purchase For Cash Shares Of Its Common Stock For An Aggregate Purchase Price Of No More Than $1.2 Billion At A Purchase Price Of Not Less Than $53.50 Per Share And Not More Than $61.50 Per Share

DaVita Commences Self-Tender Offer To Purchase For Cash Shares Of Its Common Stock For An Aggregate Purchase Price Of No More Than $1.2 Billion At A Purchase Price Of Not Less Than $53.50 Per Share And Not More Than $61.50 Per Share

DENVER, July 22, 2019 /PRNewswire/ -- DAVITA INC. (NYSE: DVA), "DaVita," a Fortune 500 ® health care provider focused on transforming care delivery to improve quality of life for patients around the globe and the largest provider of kidney care services...

DaVita Inc. Announces Preliminary Second Quarter 2019 Results And Updated Guidance For Fiscal Year 2019

DaVita Inc. Announces Preliminary Second Quarter 2019 Results And Updated Guidance For Fiscal Year 2019

DENVER, July 22, 2019 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) ("DaVita" or "Company"), today announced preliminary second quarter 2019 financial and operating results and updated guidance for fiscal year 2019.

DaVita Inc. Schedules 2nd Quarter 2019 Investor Conference Call

DaVita Inc. Schedules 2nd Quarter 2019 Investor Conference Call

DENVER, July 22, 2019 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), a leading provider of kidney care services in the United States and in 9 countries around the world, announced today that it will hold its quarterly conference call to discuss second quarter...

DaVita Statement On Advancing American Kidney Health

DaVita Statement On Advancing American Kidney Health

DENVER, July 10, 2019 /PRNewswire/ --  DaVita Kidney Care appreciates President Trump, the Administration and Secretary Azar for taking steps to improve the lives of kidney patients.

DaVita Continues To Transform Patient Care, Pushes For Continued Innovation In Kidney Care

DaVita Continues To Transform Patient Care, Pushes For Continued Innovation In Kidney Care

Affirms commitment to value-based kidney care and improving kidney disease prevention, home dialysis and transplantation

Looking for Winners of a Potential Healthcare Policy Proposal

Two companies that could benefit are CVS Health and UnitedHealth Group.

DaVita Lower as HHS Plans to Emphasize At-Home Dialysis Treatment

DaVita Lower as HHS Plans to Emphasize At-Home Dialysis Treatment

A looming federal health-care shift has the potential to shake up the $24 billion dialysis industry, in which DaVita is a leading player.

Harvest One Completes Acquisition Of Delivra

Harvest One Completes Acquisition Of Delivra

TORONTO, July 3, 2019 /PRNewswire/ - Harvest One Cannabis Inc. (TSXV: HVT, OTCQX: HRVOF - " Harvest One") and Delivra Corp.

Harvest One And Delivra Provide Update On Closing Date Of Transaction

Harvest One And Delivra Provide Update On Closing Date Of Transaction

VANCOUVER, June 28, 2019 /PRNewswire/ - Harvest One Cannabis Inc. (" Harvest One") (TSXV: HVT; OTCQX: HRVOF) and Delivra Corp.

Optum Completes Acquisition Of DaVita Medical Group From DaVita

Optum Completes Acquisition Of DaVita Medical Group From DaVita

Optum, a leading health services company, completed its acquisition of DaVita Medical Group, one of the nation's leading independent medical groups, from DaVita Inc.

Buffett's Berkshire Hathaway Closes Below $300,000

Buffett's Berkshire Hathaway Closes Below $300,000

Shares of Warren Buffett's investment vehicle, Berkshire Hathaway, ended the day below $300,000 for the first time since late March.

Buy-Write Magic With DaVita

Buy-Write Magic With DaVita

Buy-write combinations are a very powerful investment technique.

Rally or Selloff?: Cramer's 'Mad Money' Recap (Friday 5/17/19)

Rally or Selloff?: Cramer's 'Mad Money' Recap (Friday 5/17/19)

Jim Cramer says we'll need to pay close attention to retailers' earnings. Here's your game plan for next week.

Arena Pharmaceuticals, DaVita, Merck: 'Mad Money' Lightning Round

Arena Pharmaceuticals, DaVita, Merck: 'Mad Money' Lightning Round

Jim Cramer weighs in on Arena Pharmaceuticals, DaVita, Merck, Abbott Laboratories, IAC Interactive, Yext and more.

See How DaVita Ranks Among Analysts' Top Picks With Strong Buyback Activity

See How DaVita Ranks Among Analysts' Top Picks With Strong Buyback Activity

A study of analyst recommendations at the major brokerages shows that DaVita Inc is the #43 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period.

DaVita Reports On 2018 Corporate Social Responsibility Initiatives

DaVita Reports On 2018 Corporate Social Responsibility Initiatives

Company highlights achievements in patient care, community growth and sustainability

DaVita Inc. 1st Quarter 2019 Results

DaVita Inc. 1st Quarter 2019 Results

DENVER, May 7, 2019 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced results for the quarter ended March 31, 2019.

DaVita Expected to Earn 93 Cents a Share

DaVita Expected to Earn 93 Cents a Share

DaVita revenue expected to fall 1.2% to $2.8 billion.

DaVita Announces CEO Succession

DaVita Announces CEO Succession

Javier J. Rodriguez named CEO effective June 1, 2019; Kent J. Thiry to serve as Executive Chairman of the board of directors

DAVITA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates The Officers And Directors Of DaVita Inc. - DVA

DAVITA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates The Officers And Directors Of DaVita Inc. - DVA

NEW ORLEANS, April 26, 2019 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.

DaVita Inc. Schedules 1st Quarter 2019 Investor Conference Call

DaVita Inc. Schedules 1st Quarter 2019 Investor Conference Call

DENVER, April 26, 2019 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), a leading provider of kidney care services in the United States and in 10 countries around the world, announced today that it will hold its quarterly conference call to discuss first quarter...

TheStreet Quant Rating: B- (Buy)